Theranos Inc. announced Monday that it has settled two lawsuits brought by one of its biggest early investors, a move the embattled blood-testing company said would allow it to proceed with a short-term tender offer and set its sights on eventually bringing new technology to market.
Theranos on Monday touted the upside of the confidential settlement with the San Francisco-based hedge fund Partner Fund Management, which had accused the biotech startup of duping it into investing more than $96 million to prop up flawed technology.
